Pune, India, September, 2018 /press release/- Market Research Future Published a Half-Cooked Research Report on Bladder Cancer Market Research Report.
Market Research Future (MRFR)’s recent study projects that the global bladder cancer market is set to expand saliently at a robust CAGR of 12.5% during the forecast period 2017 to 2023. The rising burden of bladder cancer coupled with technological advancements in the healthcare sector is anticipated fuel growth in the market.
The risk factors related to bladder cancer such as continuous exposure to radiation, chronic bladder infection, tobacco consumption, and excessive smoking are expected to fuel demand in the bladder cancer market. Other factors responsible for favoring the bladder cancer market growth are drug innovations, the rise in aging population, government initiatives, advanced health care services, increasing healthcare expenditure, etc.
The restraints to the market growth that are expected to hold the revenue generation over the next couple of years include asymptomatic nature of the disease, drug patent expirations, high costs of therapies, the rise in the use of generic drugs, etc.
By type, the global bladder cancer market has been segmented into transitional cell bladder cancer, invasive bladder cancer, superficial bladder cancer, squamous cell bladder cancer, adenocarcinoma, and others.
By treatment, the bladder cancer market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and others.
By diagnosis, the global bladder cancer market has been segmented into urine lab tests, cystoscopy, biopsy, imaging tests, and others.
By end-user, the bladder cancer market is segmented into hospitals, clinics, cancer care centers, and others.
By region, the global bladder cancer market has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is expected to retain a dominant position globally throughout the forecast period. The factors favoring the market growth in the region include the rising burden of bladder cancer, innovations in healthcare solutions, availability of advanced healthcare infrastructure, etc. Although the U.S. is estimated to grow at a relatively slower pace, it is still likely to account for a dominant share of the regional market.
Europe is expected to remain a highly lucrative market over the assessment period. The factors encouraging the market growth in the region are the availability of better healthcare solutions coupled with a rise in bladder cancer cases. Asia Pacific is anticipated to register a high growth rate owing to increasing awareness about bladder diseases and developments in treatments.
Some of the key players profiled in the report are Bristol-Myers Squibb Company (U.S.), Celgene Corporation (U.S.), AstraZeneca Plc. (U.K.), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.S.), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (U.S.), Sanofi S.A. (France), Accord Healthcare (U.S.), Bedford Lab (U.S.), and Merck & Co. Inc. (U.S.).
In August 2018, Agilent Technologies, American public research, development, and manufacturing company, announced that it has received FDA approval for its test, PD-L1 IHC 22C3 pharmDx assay, which can be used for the identification of bladder cancer patients who might benefit from Keytruda.
In September 2018, it has been announced that BREATHALYSERS, breath test for cancer detection, will be available in GP surgeries within a few years. Initially, it will be used for detecting lung, bowel, esophagus and stomach cancer and will be expanded to the bladder, pancreas, and prostate later on.